Evaluation Only. Created with Aspose.PDF. Copyright 2002-2021 Aspose Pty Ltd.
Organic Letters
Letter
have the potential to be applied to construct natural products
and pharmaceuticals. Further studies on the detailed mechanism
and synthetic applications are ongoing in our laboratory.
Scheme 3. Mechanistic Rationalization for the Benzalation of
Substituted 3-Nitro-2H-chromene with 4-Benzylidene-2-
phenyloxazol-5(4H)-ones
ASSOCIATED CONTENT
* Supporting Information
■
S
The Supporting Information is available free of charge on the
Detailed experimental procedures, X-ray crystallographic
data characterization of compounds 3b, 3c, 3u, 4, 5c, and
5d, characterization data of compounds, and copies of
Accession Codes
CCDC 1870366−1870367, 1879543, 1885043, 1886515, and
1888928 contain the supplementary crystallographic data for
this paper. These data can be obtained free of charge via
Crystallographic Data Centre, 12 Union Road, Cambridge
CB2 1EZ, UK; fax: +44 1223 336033.
4-((Z)-benzylidene)chroman-3-one oxime under the I2/KI/
NaHCO3 system was conducted (Scheme 4). The biologically
AUTHOR INFORMATION
■
Scheme 4. Synthesis of 1,4-Diphenyl-4H-chromeno[3,4-
c]isoxazole
a b
,
Corresponding Author
ORCID
Cunde Wang: 0000-0001-5561-979X
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
Financial support of this research by the National Natural
Science Foundation of China (NNSFC 21173181) is gratefully
acknowledged by authors. A project was funded by the Priority
Academic Program Development of Jiangsu Higher Education
Institutions and the Top-notch Academic Programs Project of
Jiangsu Higher Education Institutions (PPZY2015B112).
REFERENCES
■
(1) (a) Gao, H.; Hu, B.; Dong, W.; Gao, X.; Jiang, L.; Xie, X.; Zhang, Z.
ACS Omega 2017, 2, 3168. (b) Xiang, H.; Zhao, Q.; Tang, Z.; Xiao, J.;
Xia, P.; Wang, C.; Yang, C.; Chen, X.; Yang, H. Org. Lett. 2017, 19, 146.
(c) Akram, M. O.; Bera, S.; Patil, N. T. Chem. Commun. 2016, 52,
12306. (d) Joussot, J.; Schoenfelder, A.; Larquetoux, L.; Nicolas, M.;
Suffert, J.; Blond, G. Synthesis 2016, 48, 3364. (e) Xiang, H.; Yang, C.
Org. Lett. 2014, 16, 5686. (f) Bornadiego, A.; Díaz, J.; Marcos, C. F. Adv.
Synth. Catal. 2014, 356, 718. (g) Khadem, S.; Marles, R. J. Molecules
2012, 17, 191. (h) Sharma, K. S.; Kumar, S.; Chand, K.; Kathuria, A.;
Gupta, A.; Jain, R. Curr. Med. Chem. 2011, 18, 3825. (i) Wan, J.-P.; Pan,
Y.-J. Chem. Commun. 2009, 45, 2768. (j) Vasselin, D. A.; Westwell, A.
D.; Matthews, C. S.; Bradshaw, T. D.; Stevens, M. F. G. J. Med. Chem.
2006, 49, 3973. (k) Ellis, G. P. Chromenes, Chromanones, and
Chromones: The Chemistry of Heterocyclic Compounds; John Wiley &
Sons, Inc.: New York, 1977; Vol. 31, pp 455−480.
a
Reactions of 3 (1.0 mmol) and I2 (504 mg, 2 mmol) were carried
out in the presence of NaHCO3 (168 mg, 2 mmol) and KI (332 mg, 2
mmol) in 10 mL of THF. Isolated yields are shown.
b
important 4H-chromeno[3,4-c]isoxazoles 5a−h were obtained
in 51−62% yields. The X-ray crystallography data for 5c and 5d
have been obtained, which unequivocally confirmed their
structures.
In summary, we have developed the first example of a
divergent domino benzalation reaction with a variety of 2-aryl-3-
nitro-2H-chromenes and 4-benzylidene-2-phenyloxazol-5(4H)-
ones in the presence of Cs2CO3 to generate substituted (Z)-4-
((Z)-benzylidene)chroman-3-one oxime with moderate to
excellent yields. The advantages of the current protocol include
readily available starting materials, mild reaction conditions,
good functional tolerance, and broad substrate scope. In
addition, substituted (Z)-4-((Z)-benzylidene)chroman-3-one
oximes could easily be transformed to the biologically important
4H-chromeno[3,4-c]isoxazoles with the I2/KI/NaHCO3 sys-
tem. We believe the divergent domino benzalation reaction will
(2) Son, J.; Kim, K. H.; Mo, D.-L.; Wink, D. J.; Anderson, L. L. Angew.
Chem., Int. Ed. 2017, 56, 3059.
(3) (a) Gaspar, A.; Matos, M. J.; Garrido, J.; Uriarte, E.; Borges, F.
Chem. Rev. 2014, 114, 4960. (b) Keri, R. S.; Budagumpi, S.; Pai, R. K.;
Balakrishna, R. G. Eur. J. Med. Chem. 2014, 78, 340.
(4) (a) Li, S.; Xu, H.; Cui, S.; Wu, F.; Zhang, Y.; Su, M.; Gong, Y.; Qiu,
S.; Jiao, Q.; Qin, C.; Shan, J.; Zhang, M.; Wang, J.; Yin, Q.; Xu, M.; Liu,
X.; Wang, R.; Zhu, L.; Li, J.; Xu, Y.; Jiang, H.; Zhao, Z.; Li, J.; Li, H. J.
́
Med. Chem. 2016, 59, 6772. (b) Fouque, A.; Delalande, O.; Jean, M.;
D
DOI: 10.1021/acs.orglett.9b00776
Org. Lett. XXXX, XXX, XXX−XXX